ITM Receives €188m Investment for Radiopharmaceutical Treatments

To strengthen its radiopharmaceutical treatments, ITM Isotope Technologies Munich (ITM) has obtained a financial commitment of €188 million.

The money will go towards improving and expanding ITM’s pipeline of radiopharmaceuticals, bolstering its foundation for advancement, and bringing its Phase III lead contender, ITM-11, to the market.

Along with expanding, the business will use the highly sought-after medical radioisotopes to serve its worldwide customer base and broaden its pipeline for radiopharmaceutical treatment. This approach is intended to deal with a range of difficult cancer warning signs.

ITM CEO Steffen Schuster commented: “The additional equity and continued collaboration with our existing, industry-specialised investors emphasises their confidence in our ability to drive value for the radiopharmaceutical field through our unmatched manufacturing capabilities and innovative precision oncology pipeline.’’